Assisted Reproductive Technology Market

Assisted Reproductive Technology Market Overview

The global assisted reproductive technologymarket is estimated to be worth over USD 61.45Bn in 2033 and is expected to grow at CAGR of 8.1% during the forecast period (2024-2033).

Assisted Reproductive Technology (ART) encircles medical procedures focused at addressing infertility, comprising in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and the use of donor eggs and sperm. Since the birth of the first "test-tube baby" in 1978, ART has dramatically revolutionized reproductive healthcare, offering commitment and solutions for couples struggling with infertility. Initially, ART offered a new chance for conceiving where natural methods were unsuccessful. Over the years, developments in technology and an improved understanding of reproductive biology have elevated success rates, making these treatments more dependable and widely available.

Beyond treating infertility, ART now holds a critical role in assisting individuals with genetic disorders prevent passing these conditions to their offspring. Techniques such as preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS) allow the identification of genetic abnormalities before implantation, minimizing the risk of hereditary ailments. In addition, ART has opened new avenues for single parents and same-sex couples to have biologically associated children, thusredefiningconventional family structures.

The emergence of egg freezing has further transformed fertility preservation, enabling women to hold up childbirth for personal, professional, or medical reasons without compromising future fertility. This development has offered women with greater autonomy over their reproductive timingand choices.

ART's swiftprogress has also sparked legal and ethical debates, resulting in the creation of regulatory frameworks to tacklecomplicated issues such as the rights of embryos and the welfare of donor-conceived children. These discussions are essential in ensuring that the developments in ART are implemented ethicallyand responsibly.

As ART persists to evolve with innovations like gene editing and stem cell research, the future of reproductive healthcare appears well-positioned for even more personalized and effective treatments. Overall, ART has not only extended the possibilities of parenthood but has also influenced societal norms and expectations regarding fertility and family-building.

Figure 1. Assisted Reproductive Technology: Market Size

Get more details on this report - Request Free Sample

Key Market Insights

The global assisted reproductive technology market is witnessingsignificant growth, fuelled by increasing infertility rates, developments in medical technologies, and surging societal acceptance. Latest market insights exhibit that North America and Europe dominate owing to the innovative healthcare infrastructure and high awareness, while the Asia-Pacific region is experiencingswift growth attributing to soaring medical tourism and enhancing healthcare facilities. Major developments comprise the refinement of in vitro fertilization (IVF) techniques, the incorporation of artificial intelligence to improve embryo selection, and the usage of genetic testing such as preimplantation genetic testing (PGT) to avoid hereditary diseases. Novel technologies, comprising time-lapse imaging for continuous embryo monitoring and CRISPR for potential gene editing, are revolutionizing the panorama. The market is also witnessing a rise in fertility preservation methods like egg freezing, fuelled by moving societal trends towards delayed parenthood. Furthermore, the ethical and regulatory frameworks are evolving to address emerging issues, ensuring the responsible advancement of ART. The continuous innovation and rising accessibility of these technologies propose a promising future for the ART market, poised to provide more personalized and effective reproductive solutions worldwide.

Market Dynamics

Market Drivers

Increasing Infertility Rates

Increasing infertility rates is a primary market driver for the global assisted reproductive technology market, as they immediatelyaccelerate the demand for fertility treatments and associated services. According to WHO, 1 in 6 people globally affected by infertility. Additionally, as per the reports of National Institutes of Health, the prevalence rate of infertility has been reported to escalate from 3.5% to 16.7% in more developed nations and from 6.9% to 9.3% in less-developed ones. 

Infertility, affecting millions globally, can be attributed to different factors comprising lifestyle variations, postponed marriages, environmental pollution, and increasing incidences of health conditions such as obesity and diabetes. As more couples witness challenges in conceiving naturally, the necessity for effective fertility solutions becomes crucial. ART provides a scale of treatments, such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), which have proven successful in helping couples achieve pregnancy. This soaring demand is indicated in the growing number of fertility clinics and the expanding scope of services offered. In addition, higher societal acceptance and diminished stigma around seeking fertility treatment encourage more individuals to explore ART. Insurance coverage and government initiatives in some regions further promote market growth by making these technologies more accessible. As a consequence, increasing infertility rates propel the ART market's expansion, fuelling technological developments and improving the development of innovative and personalized reproductive solutions to fulfil the needs of a diverse patient population.

Market Restraints

With regard to numerous advantages of Assisted Reproductive Technology, the market faces several challenges due to the unique characteristics and requirements associated with these potent pharmaceutical products. Some of the key market challenges include:

• High Cost of Treatment: Assisted Reproductive Technology (ART) proceduresare often expensive, making them inaccessible to a major portion of the population. The high costs related to these treatments, comprising medication, laboratory fees, and multiple cycles required for success, can be prohibitive for several individuals and couples, specifically in regions without insurance coverage or government subsidies.
• Ethical and Legal Challenges: The ART market is subject to intricate ethical and legal considerations, which can vary significantly across various countries and regions. Issues such as the rights of embryos, the regulation of surrogacy, the use of donor gametes, and the implications of genetic testing and modification raise ethical debates and can result in restrictive legal frameworks. These challenges can deter the market's growth by creating barriers to the adoption and implementation of ART technologies and impeding the availability of services in certain areas.

Get more details on this report - Request Free Sample

Market Opportunity

Growing Awareness & Acceptance

Since public knowledge about infertility and its treatments enlarges, more individuals and couples become informed about the available alternatives to address reproductive constraints. Educational campaigns, media coverage, and advocacy by healthcare professionals contribute to lessen the stigma related to infertility and ART procedures. This greater acceptance stimulates more people to seek fertility treatments, accelerating demand for ART services. In addition to that, the normalization of ART through success stories and endorsements by public figures helps foster a positive perception, making it more socially acceptable to pursue these treatments. The increasing awareness also urges healthcare providers to extend the scope of their services and invest in innovative technologies to meet the soaring demand. As acceptance widens, insurance companies and policymakers are more likely to comprise ART in healthcare coverage plans and support regulatory frameworks that support access to these services. As a result, the increasing awareness and acceptance of ART not only propel market growth by appealing a broader patient base but also spur continuous advancements and investments in the field, improving the overall quality and availability of reproductive healthcare solutions.

Market Trends

• Expansion of Fertility Preservation Services: There is an elevating trend towards the expansion of fertility preservation services, such as egg, sperm, and embryo freezing. This trend is fuelled by societal shifts towards postponed parenthood due to career, education, or personal reasons, as well as by medical needs such as cancer treatments that can affect fertility. Developments in cryopreservation techniques have enhanced the viability of preserved gametes and embryos, making fertility preservation a viable alternatives for a broader demographic. This trend is also supported by increased awareness and acceptance of fertility preservation, resulting in a surge in demand for these services within the ART market.
• Growth in Cross-Border Reproductive Care (CBRC): The global ART market is experiencing a rise in cross-border reproductive care, where patients travel to other countries to access fertility treatments. This trend is driven by factors such as lesser treatment costs, availability of innovative medical technologies, more favourable legal and regulatory environments, and briefer waiting times in destination countries. Medical tourism in fertility care is specifically prominent in regions like Europe and Southeast Asia, where high-quality ART services are provided at a fraction of the cost in comparison to Western countries. This trend not only extends the market reach for ART providers but also support the exchange of expertise and best practices across borders, improving the overall quality of reproductive healthcare.

Assisted Reproductive Technology Market: Key Segments

By Technology

• In-Vitro Fertilization
• Artificial Insemination
• Surrogacy

By Procedure

• Frozen Donor
• Frozen Non Donor
• Fresh Donor
• Fresh Non Donor
• Embryo Banking

By Application

• Fertility Clinics
• Hospitals
• Others

By Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

Figure 4. Assisted Reproductive Technology Market: Distribution by Region

Get more details on this report - Request Free Sample

Assisted Reproductive Technology Market: Regional Analysis

North America is expected to dominate the market owing to a combination of increasing infertility rates and a escalated awareness of available fertility treatments. The region hasstrong and well-established healthcare infrastructure, along with high disposable income, allowsincreased access to and adoption of ART procedures. In addition, the presence of leading ART clinics and research facilities further aids the market growth in the region.Asia-Pacific is anticipated to witness robust growth in the forthcomingyearsowing to several factors, comprising the soaring trend of late family planning adoption, where couples are choosing to have children at a later age, resulting in a greater demand for ART services. 

Leading Assisted Reproductive Technology Developers

Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunities associated with the Assisted Reproductive Technologymarket, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the biopharmaceutical industry. Key takeaways of the Assisted Reproductive Technologymarket are briefly discussed below.

The report includes the list of players operating in the global Assisted Reproductive Technology market. Some of the key players include:

• Anecova (Switzerland)
• Bloom Fertility Centre (India)
• California Cryobank (U.S.)
• Celmatix Inc. (U.S.)
• CooperSurgical (U.S.)
• Esco Micro Pte Ltd. (Singapore)
• Ferring B.V. (Switzerland)
• FUJIFILM Irvine Scientific (U.S.)
• Genea Limited (Australia)
• ICU Medical, Inc. (U.S.)
• INVO Bioscience (U.S.)
• Laboratoire CCD (France)
• Merck KGaA (Germany)
• Nidacon International AB (Sweden)
• Nikon Instruments Inc. (U.S.)

Assisted Reproductive Technology Market: Key Developments

• In June 2024, CooperSurgical announced that it has acquired ZyM?t Fertility, a subsidiary of DxNow, Inc. ZyM?t’s global presence commercializing a first-of-its-kind sperm separation device will add to CooperSurgical’s portfolio of assisted reproductive technology (ART) products and services.
• In June 2022, Inception Fertility expanded its ecosystem to include the launch of HavenCryo, a long-term reproductive tissue and cryopreservation storage solution that offers a unique experience for fertility providers and patients.

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments, as defined in the below table: